A study to check if Sanjeevanam Roll helps pain relief of headache, common cold, nasal congestion and joint sprain disorders

A three arm, open label, interventional study to evaluate the safety, efficacy and tolerability of Sanjeevanam Roll on for pain relief in participants with headache, common cold, nasal congestion and joint sprain disorders - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/106625

Enrollment

Registered

2026-03-20

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J00- Acute nasopharyngitis [common cold]

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Participants who are able to understand written and/or verbal instructions and are ready to comply with all study requirements with a willingness to participate and give written informed consent voluntarily Participants clinically diagnosed with one of the following: -Headache (tension-type or non-migraine headache) - as per The International Classification of Headache Disorders 3rd edition (ICHD-3) criteria Nasal congestion due to common cold or allergic rhinitis Acute joint sprain (Grade 1 or mild or Grade 2) Participants with pain score grater then equal 3/10 (based on numeric pain rating scale) during the past 1 week.

Exclusion criteria

Exclusion criteria: Severe headache disorders (e.g., migraine, cluster headache) Nasal polyps, or active nasal infections Severe joint injuries (Grade 3 sprain, fractures, or dislocations) Broken skin, wounds, dermatitis, or active skin infections at the application site Use of other topical analgesics, nasal decongestants, or pain relief products at the application site during the study period Use of systemic analgesics, steroids, or muscle relaxants that may interfere with study outcomes Participation in an investigational drug trial during the last 30 days. Immuno-compromised (history) individuals including known HIV positive participants or participants who are on treatment with steroids or immunomodulators. Known hypersensitivity or allergy to any ingredient of Sanjeevanam Roll-On Participants of vulnerable group (e.g. seriously ill, mentally challenged). Pregnant or lactating women History of drug or alcohol abuse during the last 3 months.

Design outcomes

Primary

Measure	Time frame
Time to onset of relief of pain Time to achieve complete relief of pain Reduction in pain score on numeric pain rating scale (VAS) Assessment of pain relief by using McGill Pain questionnaire. Symptom-specific assessments for each arm: Based on complete relief of pain. Headache relief score Nasal congestion relief score (VAS score) Joint pain and functional improvement score Participant s overall satisfaction for pain relief on a 7- point Likert Satisfaction scale SF12 quality of life scoring Participant Global Assessment of EffectivenessTimepoint: 0 mins to 120 mins ,day 0, day 2 and day 7	—

Measure

Time frame

Time to onset of relief of pain Time to achieve complete relief of pain Reduction in pain score on numeric pain rating scale (VAS) Assessment of pain relief by using McGill Pain questionnaire. Symptom-specific assessments for each arm: Based on complete relief of pain. Headache relief score Nasal congestion relief score (VAS score) Joint pain and functional improvement score Participant s overall satisfaction for pain relief on a 7- point Likert Satisfaction scale SF12 quality of life scoring Participant Global Assessment of EffectivenessTimepoint: 0 mins to 120 mins ,day 0, day 2 and day 7

—

Secondary

Measure	Time frame
Adverse events (AE) will be monitored throughout the study periodTimepoint: day 0, day 2 and day 7 - post dose	—

Countries

India

Contacts

Public ContactDr Gayathri Sivakumar

DK Elite Health Care Centre

saheerose@gmail.com09943805988

Outcome results